• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Health Policy for Dialysis Care in Canada and the United States.加拿大和美国的透析护理健康政策。
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1669-1677. doi: 10.2215/CJN.14961219. Epub 2020 Jun 25.
2
Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation.透析设施所有权对患者生存及移植转诊的影响。
N Engl J Med. 1999 Nov 25;341(22):1653-60. doi: 10.1056/NEJM199911253412205.
3
Facility Practice Variation to Help Understand the Effects of Public Policy: Insights from the Dialysis Outcomes and Practice Patterns Study (DOPPS).设施实践差异有助于了解公共政策的影响:来自透析结局和实践模式研究 (DOPPS) 的见解。
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):190-199. doi: 10.2215/CJN.03930416. Epub 2016 Nov 10.
4
Association of VA Payment Reform for Dialysis with Spending, Access to Care, and Outcomes for Veterans with ESKD.VA 透析支付改革与 ESKD 退伍军人的支出、获得护理和结果的关联。
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1631-1639. doi: 10.2215/CJN.02100220. Epub 2020 Sep 22.
5
Proposed conditions for coverage directed toward dialysis facilities.针对透析设施提出的覆盖条件。
Health Care Law Mon. 2005 Apr:3-11.
6
Association between Freestanding Dialysis Facility Size and Medicare Quality Incentive Program Performance Scores.独立透析中心规模与医疗保险质量激励计划绩效评分之间的关联。
Am J Nephrol. 2019;49(1):64-73. doi: 10.1159/000495262. Epub 2018 Dec 17.
7
Practice patterns, case mix, Medicare payment policy, and dialysis facility costs.实践模式、病例组合、医疗保险支付政策和透析设施成本。
Health Serv Res. 1999 Feb;33(6):1567-92.
8
Consolidation in the Dialysis Industry, Patient Choice, and Local Market Competition.透析行业的整合、患者选择与本地市场竞争。
Clin J Am Soc Nephrol. 2017 Mar 7;12(3):536-545. doi: 10.2215/CJN.06340616. Epub 2016 Nov 9.
9
For-profit versus not-for-profit dialysis care for children with end stage renal disease.终末期肾病儿童的营利性与非营利性透析治疗
Pediatrics. 1999 Sep;104(3 Pt 1):519-24. doi: 10.1542/peds.104.3.519.
10
Understanding financial risk models: Implicationsfor nephrology practices and dialysis centers.理解金融风险模型:对肾脏病医疗实践及透析中心的影响
Nephrol News Issues. 2016 Mar;30(3):26-8, 30-3.

引用本文的文献

1
Bundle Fix?: We Need an Act of Congress.捆绑修复?:我们需要国会立法。
J Am Soc Nephrol. 2025 May 1;36(5):981-983. doi: 10.1681/ASN.0000000664. Epub 2025 Feb 14.
2
Overview of global healthcare policies for patients with chronic kidney disease: an integrative literature review.全球慢性肾脏病患者医疗政策概述:综合文献回顾。
Einstein (Sao Paulo). 2024 Jul 19;22:eRW0519. doi: 10.31744/einstein_journal/2024RW0519. eCollection 2024.
3
Evaluation and Measurement Properties of a Patient-Reported Experience Measure for Home Dialysis.居家透析患者报告体验量表的评估和测量特性。
Clin J Am Soc Nephrol. 2024 May 1;19(5):602-609. doi: 10.2215/CJN.0000000000000429. Epub 2024 Jan 23.
4
Peritoneal Dialysis Catheter Complications after Insertion by Surgeons, Radiologists, or Nephrologists.外科医生、放射科医生或肾脏病医生置管后腹膜透析导管相关并发症。
J Am Soc Nephrol. 2024 Jan 1;35(1):85-93. doi: 10.1681/ASN.0000000000000250. Epub 2023 Oct 17.
5
Medium Cutoff Versus High-Flux Hemodialysis Membranes and Clinical Outcomes: A Cohort Study Using Inverse Probability Treatment Weighting.中截留量与高通量血液透析膜及临床结局:一项使用逆概率处理加权的队列研究
Kidney Med. 2022 Feb 7;4(4):100431. doi: 10.1016/j.xkme.2022.100431. eCollection 2022 Apr.
6
A history of uraemic toxicity and of the European Uraemic Toxin Work Group (EUTox).尿毒症毒性史与欧洲尿毒症毒素工作组(EUTox)。
Clin Kidney J. 2021 Jan 24;14(6):1514-1523. doi: 10.1093/ckj/sfab011. eCollection 2021 Jun.

加拿大和美国的透析护理健康政策。

Health Policy for Dialysis Care in Canada and the United States.

机构信息

Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Nephrology Section, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, European Kidney Health Alliance.

出版信息

Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1669-1677. doi: 10.2215/CJN.14961219. Epub 2020 Jun 25.

DOI:10.2215/CJN.14961219
PMID:32586926
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7646249/
Abstract

Contemporary dialysis treatment for chronic kidney failure is complex, is associated with poor clinical outcomes, and leads to high health costs, all of which pose substantial policy challenges. Despite similar policy goals and universal access for their kidney failure programs, the United States and Canada have taken very different approaches to dealing with these challenges. While US dialysis care is primarily government funded and delivered predominantly by private for-profit providers, Canadian dialysis care is also government funded but delivered almost exclusively in public facilities. Differences also exist for regulatory mechanisms and the policy incentives that may influence the behavior of providers and facilities. These differences in health policy are associated with significant variation in clinical outcomes: mortality among patients on dialysis is consistently lower in Canada than in the United States, although the gap has narrowed in recent years. The observed heterogeneity in policy and outcomes offers important potential opportunities for each health system to learn from the other. This article compares and contrasts transnational dialysis-related health policies, focusing on key levers including payment, finance, regulation, and organization. We also describe how policy levers can incentivize favorable practice patterns to support high-quality/high-value, person-centered care and to catalyze the emergence of transformative technologies for alternative kidney replacement strategies.

摘要

当代慢性肾衰竭的透析治疗较为复杂,与较差的临床结局相关,并导致高昂的卫生保健费用,所有这些都对政策制定提出了重大挑战。尽管美加两国的肾衰竭项目具有相似的政策目标和全民覆盖,但在应对这些挑战方面却采取了非常不同的方法。在美国,透析护理主要由政府提供资金,并主要由私营营利性供应商提供;而在加拿大,透析护理同样由政府提供资金,但几乎完全在公立机构中提供。监管机制和政策激励措施方面也存在差异,这些差异可能会影响提供者和医疗机构的行为。这些卫生政策的差异与临床结局的显著差异相关:接受透析治疗的患者的死亡率在加拿大一直低于美国,尽管近年来差距有所缩小。政策和结果的这种异质性为每个卫生系统相互学习提供了重要的潜在机会。本文比较和对比了跨国透析相关的卫生政策,重点关注包括支付、融资、监管和组织在内的关键杠杆。我们还描述了政策杠杆如何激励有利的实践模式,以支持高质量/高价值、以患者为中心的护理,并推动替代肾脏替代策略的变革性技术的出现。